Olmesartan reduces oxidative stress in the brain of stroke-prone spontaneously hypertensive rats assessed by an in vivo ESR method

Shuichiro Araki, Yoshitaka Hirooka, Takuya Kishi, Keiji Yasukawa, Hideo Utsumi, Kenji Sunagawa

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

We previously showed that oxidative stress in the brain is involved in the neural mechanisms of hypertension. Therefore, olmesartan, an angiotensin type 1 receptor blocker, might affect oxidative stress in the brains of stroke-prone spontaneously hypertensive rats (SHRSP). Here, we evaluated the effects of olmesartan treatment using an in vivo electron spin resonance (ESR)/spin probe technique. Two groups of SHRSP were treated with either olmesartan (10 mg kg 1 day 1) or hydralazine (Hyd, 20 mg kg 1 day 1)/hydrochlorothiazide (HCT, 4.5 mg 1 kg day 1) for 30 days (n5 for each). Systolic blood pressure decreased similarly in both groups after treatment. Heart rate and urinary norepinephrine (NE) excretion increased in rats treated with Hyd/HCT, but not in those treated with olmesartan. The in vivo ESR signal decay rates of the blood-brain barrier-permeable spin probe methoxycarbonyl-PROXYL were significantly higher in SHRSP brains than in age-matched normotensive Wistar-Kyoto rat brains (P0.01; n6 for each). Olmesartan attenuated the ESR signal decay rates in SHRSP brains, but Hyd/HCT did not. Intracerebroventricular infusion of active form of olmesartan, RNH-6270, reduced blood pressure and NE excretion, and the ESR signal decay rate was reduced in SHRSP brains. These findings indicate that olmesartan has anti-oxidative property in the brain without stimulating reflex-mediated sympathetic activity in SHRSP.

Original languageEnglish
Pages (from-to)1091-1096
Number of pages6
JournalHypertension Research
Volume32
Issue number12
DOIs
Publication statusPublished - Dec 23 2009

Fingerprint

Electron Spin Resonance Spectroscopy
Inbred SHR Rats
Oxidative Stress
Stroke
Brain
Blood Pressure
Norepinephrine
Intraventricular Infusions
Angiotensin II Type 1 Receptor Blockers
Hydralazine
Hydrochlorothiazide
Inbred WKY Rats
olmesartan
Blood-Brain Barrier
Reflex
Heart Rate
Hypertension
Therapeutics

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Olmesartan reduces oxidative stress in the brain of stroke-prone spontaneously hypertensive rats assessed by an in vivo ESR method. / Araki, Shuichiro; Hirooka, Yoshitaka; Kishi, Takuya; Yasukawa, Keiji; Utsumi, Hideo; Sunagawa, Kenji.

In: Hypertension Research, Vol. 32, No. 12, 23.12.2009, p. 1091-1096.

Research output: Contribution to journalArticle

Araki, Shuichiro ; Hirooka, Yoshitaka ; Kishi, Takuya ; Yasukawa, Keiji ; Utsumi, Hideo ; Sunagawa, Kenji. / Olmesartan reduces oxidative stress in the brain of stroke-prone spontaneously hypertensive rats assessed by an in vivo ESR method. In: Hypertension Research. 2009 ; Vol. 32, No. 12. pp. 1091-1096.
@article{cf916d1bdc864f8fb3becd439b97b31d,
title = "Olmesartan reduces oxidative stress in the brain of stroke-prone spontaneously hypertensive rats assessed by an in vivo ESR method",
abstract = "We previously showed that oxidative stress in the brain is involved in the neural mechanisms of hypertension. Therefore, olmesartan, an angiotensin type 1 receptor blocker, might affect oxidative stress in the brains of stroke-prone spontaneously hypertensive rats (SHRSP). Here, we evaluated the effects of olmesartan treatment using an in vivo electron spin resonance (ESR)/spin probe technique. Two groups of SHRSP were treated with either olmesartan (10 mg kg 1 day 1) or hydralazine (Hyd, 20 mg kg 1 day 1)/hydrochlorothiazide (HCT, 4.5 mg 1 kg day 1) for 30 days (n5 for each). Systolic blood pressure decreased similarly in both groups after treatment. Heart rate and urinary norepinephrine (NE) excretion increased in rats treated with Hyd/HCT, but not in those treated with olmesartan. The in vivo ESR signal decay rates of the blood-brain barrier-permeable spin probe methoxycarbonyl-PROXYL were significantly higher in SHRSP brains than in age-matched normotensive Wistar-Kyoto rat brains (P0.01; n6 for each). Olmesartan attenuated the ESR signal decay rates in SHRSP brains, but Hyd/HCT did not. Intracerebroventricular infusion of active form of olmesartan, RNH-6270, reduced blood pressure and NE excretion, and the ESR signal decay rate was reduced in SHRSP brains. These findings indicate that olmesartan has anti-oxidative property in the brain without stimulating reflex-mediated sympathetic activity in SHRSP.",
author = "Shuichiro Araki and Yoshitaka Hirooka and Takuya Kishi and Keiji Yasukawa and Hideo Utsumi and Kenji Sunagawa",
year = "2009",
month = "12",
day = "23",
doi = "10.1038/hr.2009.160",
language = "English",
volume = "32",
pages = "1091--1096",
journal = "Hypertension Research",
issn = "0916-9636",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Olmesartan reduces oxidative stress in the brain of stroke-prone spontaneously hypertensive rats assessed by an in vivo ESR method

AU - Araki, Shuichiro

AU - Hirooka, Yoshitaka

AU - Kishi, Takuya

AU - Yasukawa, Keiji

AU - Utsumi, Hideo

AU - Sunagawa, Kenji

PY - 2009/12/23

Y1 - 2009/12/23

N2 - We previously showed that oxidative stress in the brain is involved in the neural mechanisms of hypertension. Therefore, olmesartan, an angiotensin type 1 receptor blocker, might affect oxidative stress in the brains of stroke-prone spontaneously hypertensive rats (SHRSP). Here, we evaluated the effects of olmesartan treatment using an in vivo electron spin resonance (ESR)/spin probe technique. Two groups of SHRSP were treated with either olmesartan (10 mg kg 1 day 1) or hydralazine (Hyd, 20 mg kg 1 day 1)/hydrochlorothiazide (HCT, 4.5 mg 1 kg day 1) for 30 days (n5 for each). Systolic blood pressure decreased similarly in both groups after treatment. Heart rate and urinary norepinephrine (NE) excretion increased in rats treated with Hyd/HCT, but not in those treated with olmesartan. The in vivo ESR signal decay rates of the blood-brain barrier-permeable spin probe methoxycarbonyl-PROXYL were significantly higher in SHRSP brains than in age-matched normotensive Wistar-Kyoto rat brains (P0.01; n6 for each). Olmesartan attenuated the ESR signal decay rates in SHRSP brains, but Hyd/HCT did not. Intracerebroventricular infusion of active form of olmesartan, RNH-6270, reduced blood pressure and NE excretion, and the ESR signal decay rate was reduced in SHRSP brains. These findings indicate that olmesartan has anti-oxidative property in the brain without stimulating reflex-mediated sympathetic activity in SHRSP.

AB - We previously showed that oxidative stress in the brain is involved in the neural mechanisms of hypertension. Therefore, olmesartan, an angiotensin type 1 receptor blocker, might affect oxidative stress in the brains of stroke-prone spontaneously hypertensive rats (SHRSP). Here, we evaluated the effects of olmesartan treatment using an in vivo electron spin resonance (ESR)/spin probe technique. Two groups of SHRSP were treated with either olmesartan (10 mg kg 1 day 1) or hydralazine (Hyd, 20 mg kg 1 day 1)/hydrochlorothiazide (HCT, 4.5 mg 1 kg day 1) for 30 days (n5 for each). Systolic blood pressure decreased similarly in both groups after treatment. Heart rate and urinary norepinephrine (NE) excretion increased in rats treated with Hyd/HCT, but not in those treated with olmesartan. The in vivo ESR signal decay rates of the blood-brain barrier-permeable spin probe methoxycarbonyl-PROXYL were significantly higher in SHRSP brains than in age-matched normotensive Wistar-Kyoto rat brains (P0.01; n6 for each). Olmesartan attenuated the ESR signal decay rates in SHRSP brains, but Hyd/HCT did not. Intracerebroventricular infusion of active form of olmesartan, RNH-6270, reduced blood pressure and NE excretion, and the ESR signal decay rate was reduced in SHRSP brains. These findings indicate that olmesartan has anti-oxidative property in the brain without stimulating reflex-mediated sympathetic activity in SHRSP.

UR - http://www.scopus.com/inward/record.url?scp=73849116449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73849116449&partnerID=8YFLogxK

U2 - 10.1038/hr.2009.160

DO - 10.1038/hr.2009.160

M3 - Article

VL - 32

SP - 1091

EP - 1096

JO - Hypertension Research

JF - Hypertension Research

SN - 0916-9636

IS - 12

ER -